365 related articles for article (PubMed ID: 30489033)
1. Evaluating radium-223 response in metastatic castration-resistant prostate cancer with imaging.
Iizuka J
Asia Pac J Clin Oncol; 2018 Nov; 14 Suppl 5():16-23. PubMed ID: 30489033
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of bone metastases by 18F-choline PET/CT in a patient with castration-resistant prostate cancer treated with radium-223.
Scalzi P; Baiocco C; Genovese S; Trevisan A; Sirotova Z; Poti C
Urologia; 2017 Feb; 84(1):61-64. PubMed ID: 27911459
[TBL] [Abstract][Full Text] [Related]
3. Optimal usage of radium-223 in metastatic castration-resistant prostate cancer.
Cha TL; Wu TT; Vogelzang NJ; Huang CY; Huang SP; Lin CC; Ou YC; Pang ST; Shen DH; Wu WJ; Chang WY
J Formos Med Assoc; 2017 Nov; 116(11):825-836. PubMed ID: 29046247
[TBL] [Abstract][Full Text] [Related]
4. Final Outcome of 223Ra-therapy and the Role of 18F-fluoride-PET in Response Evaluation in Metastatic Castration-resistant Prostate Cancer-A Single Institution Experience.
Kairemo K; Milton DR; Etchebehere E; Rohren EM; Macapinlac HA
Curr Radiopharm; 2018; 11(2):147-152. PubMed ID: 29956640
[TBL] [Abstract][Full Text] [Related]
5. [Bone-specific therapy with radium-223 dichloride : Castration-resistant prostate cancer with symptomatic bone metastases].
Tauber R; Gschwend J; Scheidhauer K; Eiber M; Krönke M
Urologe A; 2017 Jan; 56(1):24-31. PubMed ID: 28058455
[TBL] [Abstract][Full Text] [Related]
6. Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases.
Uemura H; Uemura H; Nagamori S; Wakumoto Y; Kimura G; Kikukawa H; Yokomizo A; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Akagawa T; Matsubara N
Int J Clin Oncol; 2019 May; 24(5):557-566. PubMed ID: 30875000
[TBL] [Abstract][Full Text] [Related]
7. Radium 223: how can we optimize this new tool for metastatic castration-resistant prostate cancer?
Dorff TB; Gross ME
Am Soc Clin Oncol Educ Book; 2015; ():e270-3. PubMed ID: 25993185
[TBL] [Abstract][Full Text] [Related]
8. Lymph Node Response in a Patient With Metastatic Castration-resistant Prostate Cancer Treated With Radium-223.
Poon DMC; Wong KCW
Clin Genitourin Cancer; 2018 Apr; 16(2):e397-e401. PubMed ID: 29174502
[No Abstract] [Full Text] [Related]
9. Selection and monitoring of patients with metastatic castration-resistant prostate cancer for treatment with radium-223.
Rodriguez-Vida A; Torregrosa MD; Pinto Á; Climent MÁ; Olmos D; Carles J
Clin Transl Oncol; 2018 Jun; 20(6):679-686. PubMed ID: 29098556
[TBL] [Abstract][Full Text] [Related]
10. Is There a Flare Phenomenon on Bone Scintigraphy in Men With Advanced Prostate Cancer Treated With Radium-223?
Isensee G; Péporté A; Müller J; Schmid S; Gillessen S; Omlin A
Clin Genitourin Cancer; 2018 Oct; 16(5):349-354. PubMed ID: 29778323
[TBL] [Abstract][Full Text] [Related]
11. Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases-analysis of an international multicenter database.
Keizman D; Fosboel MO; Reichegger H; Peer A; Rosenbaum E; Desax MC; Neiman V; Petersen PM; Mueller J; Cathomas R; Gottfried M; Dresler H; Sarid D; Mermershtain W; Rouvinov K; Mortensen J; Gillessen S; Daugaard G; Omlin A
Prostate Cancer Prostatic Dis; 2017 Sep; 20(3):289-293. PubMed ID: 28244493
[TBL] [Abstract][Full Text] [Related]
12. The value of baseline 18F-sodium fluoride and 18F-choline PET activity for identifying responders to radium-223 treatment in castration-resistant prostate cancer bone metastases.
Donners R; Tunariu N; Tovey H; Hall E; Chua S; Cook G; Du Y; Blackledge MD; Parker CC; Koh DM
Eur Radiol; 2024 Feb; 34(2):1146-1154. PubMed ID: 37615760
[TBL] [Abstract][Full Text] [Related]
13. Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer.
Nilsson S
Curr Oncol Rep; 2016 Feb; 18(2):14. PubMed ID: 26779616
[TBL] [Abstract][Full Text] [Related]
14. Baseline
García Vicente AM; González García B; Amo-Salas M; García Carbonero I; Cassinello Espinosa J; Gómez-Aldaraví Gutierrez JL; Suarez Hinojosa L; Soriano Castrejón Á
Clin Transl Oncol; 2019 Mar; 21(3):289-297. PubMed ID: 30006674
[TBL] [Abstract][Full Text] [Related]
15. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.
Sartor O; Coleman R; Nilsson S; Heinrich D; Helle SI; O'Sullivan JM; Fosså SD; Chodacki A; Wiechno P; Logue J; Widmark A; Johannessen DC; Hoskin P; James ND; Solberg A; Syndikus I; Vogelzang NJ; O'Bryan-Tear CG; Shan M; Bruland ØS; Parker C
Lancet Oncol; 2014 Jun; 15(7):738-46. PubMed ID: 24836273
[TBL] [Abstract][Full Text] [Related]
16. Response Assessment of 223Ra Treatment: Should a Fluorocholine PET/CT Be Performed?
García Vicente AM; Soriano Castrejón Á; Alvarez Cabellos R; Sanchez Gil B; Mohedano Mohedano N
Clin Nucl Med; 2017 Oct; 42(10):761-765. PubMed ID: 28806246
[TBL] [Abstract][Full Text] [Related]
17. Uptake of Radium-223 Dichloride and Early [
Letellier A; Johnson AC; Kit NH; Savigny JF; Batalla A; Parienti JJ; Aide N
Mol Imaging Biol; 2018 Jun; 20(3):482-491. PubMed ID: 29027074
[TBL] [Abstract][Full Text] [Related]
18. Patterns of response and progression in bone and soft tissue during and after treatment with radium-223 for metastatic castrate-resistant prostate cancer.
McNamara MA; Oyekunle T; Chin BB; Oldan J; Anand A; Ritz M; Shantzer L; Anand M; Armstrong AJ; George DJ
Prostate; 2019 Jul; 79(10):1106-1116. PubMed ID: 31045266
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial.
Hoskin P; Sartor O; O'Sullivan JM; Johannessen DC; Helle SI; Logue J; Bottomley D; Nilsson S; Vogelzang NJ; Fang F; Wahba M; Aksnes AK; Parker C
Lancet Oncol; 2014 Nov; 15(12):1397-406. PubMed ID: 25439694
[TBL] [Abstract][Full Text] [Related]
20. Management of metastatic castration-resistant prostate cancer: A focus on radium-223: Opinions and suggestions from an expert multidisciplinary panel.
Baldari S; Boni G; Bortolus R; Caffo O; Conti G; De Vincentis G; Monari F; Procopio G; Santini D; Seregni E; Valdagni R
Crit Rev Oncol Hematol; 2017 May; 113():43-51. PubMed ID: 28427521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
